nodes	percent_of_prediction	percent_of_DWPC	metapath
Captopril—MMP9—amyotrophic lateral sclerosis	0.666	1	CbGaD
Captopril—REN—arm—amyotrophic lateral sclerosis	0.00767	0.0587	CbGeAlD
Captopril—MMP2—hindlimb—amyotrophic lateral sclerosis	0.00738	0.0565	CbGeAlD
Captopril—Nephritis—Riluzole—amyotrophic lateral sclerosis	0.00697	0.0662	CcSEcCtD
Captopril—REN—appendage—amyotrophic lateral sclerosis	0.00689	0.0528	CbGeAlD
Captopril—MMP9—hindlimb—amyotrophic lateral sclerosis	0.00642	0.0492	CbGeAlD
Captopril—Traumatic liver injury—Riluzole—amyotrophic lateral sclerosis	0.00639	0.0607	CcSEcCtD
Captopril—MMP2—appendage—amyotrophic lateral sclerosis	0.00633	0.0485	CbGeAlD
Captopril—REN—peripheral nervous system—amyotrophic lateral sclerosis	0.00627	0.048	CbGeAlD
Captopril—F2—forelimb—amyotrophic lateral sclerosis	0.00623	0.0477	CbGeAlD
Captopril—F2—hindlimb—amyotrophic lateral sclerosis	0.0056	0.0429	CbGeAlD
Captopril—MMP9—appendage—amyotrophic lateral sclerosis	0.00551	0.0422	CbGeAlD
Captopril—REN—nerve—amyotrophic lateral sclerosis	0.00488	0.0374	CbGeAlD
Captopril—F2—appendage—amyotrophic lateral sclerosis	0.00481	0.0368	CbGeAlD
Captopril—ACE—forelimb—amyotrophic lateral sclerosis	0.0038	0.0291	CbGeAlD
Captopril—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.00379	0.036	CcSEcCtD
Captopril—REN—hindbrain—amyotrophic lateral sclerosis	0.00366	0.028	CbGeAlD
Captopril—ACE—hindlimb—amyotrophic lateral sclerosis	0.00342	0.0262	CbGeAlD
Captopril—ACE—arm—amyotrophic lateral sclerosis	0.00327	0.025	CbGeAlD
Captopril—LTA4H—embryo—amyotrophic lateral sclerosis	0.00296	0.0227	CbGeAlD
Captopril—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.00294	0.0279	CcSEcCtD
Captopril—ACE—appendage—amyotrophic lateral sclerosis	0.00294	0.0225	CbGeAlD
Captopril—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.00283	0.0269	CcSEcCtD
Captopril—ACE—peripheral nervous system—amyotrophic lateral sclerosis	0.00267	0.0204	CbGeAlD
Captopril—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.00258	0.0245	CcSEcCtD
Captopril—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00252	0.0239	CcSEcCtD
Captopril—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.00238	0.0226	CcSEcCtD
Captopril—MMP2—embryo—amyotrophic lateral sclerosis	0.0021	0.0161	CbGeAlD
Captopril—REN—brainstem—amyotrophic lateral sclerosis	0.0021	0.0161	CbGeAlD
Captopril—ACE—nerve—amyotrophic lateral sclerosis	0.00208	0.0159	CbGeAlD
Captopril—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00203	0.0192	CcSEcCtD
Captopril—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00199	0.0189	CcSEcCtD
Captopril—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00197	0.0187	CcSEcCtD
Captopril—LTA4H—medulla oblongata—amyotrophic lateral sclerosis	0.00189	0.0145	CbGeAlD
Captopril—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00183	0.0174	CcSEcCtD
Captopril—MMP9—embryo—amyotrophic lateral sclerosis	0.00183	0.014	CbGeAlD
Captopril—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.00179	0.017	CcSEcCtD
Captopril—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00174	0.0165	CcSEcCtD
Captopril—LTA4H—spinal cord—amyotrophic lateral sclerosis	0.00169	0.0129	CbGeAlD
Captopril—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00164	0.0156	CcSEcCtD
Captopril—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00163	0.0154	CcSEcCtD
Captopril—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00158	0.015	CcSEcCtD
Captopril—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00152	0.0145	CcSEcCtD
Captopril—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0139	CcSEcCtD
Captopril—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00146	0.0138	CcSEcCtD
Captopril—LTA4H—nervous system—amyotrophic lateral sclerosis	0.00142	0.0109	CbGeAlD
Captopril—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00142	0.0135	CcSEcCtD
Captopril—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.0014	0.0133	CcSEcCtD
Captopril—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00138	0.0131	CcSEcCtD
Captopril—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00138	0.0131	CcSEcCtD
Captopril—LTA4H—central nervous system—amyotrophic lateral sclerosis	0.00137	0.0105	CbGeAlD
Captopril—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00136	0.0129	CcSEcCtD
Captopril—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00135	0.0128	CcSEcCtD
Captopril—MMP2—medulla oblongata—amyotrophic lateral sclerosis	0.00134	0.0103	CbGeAlD
Captopril—LTA4H—cerebellum—amyotrophic lateral sclerosis	0.00134	0.0103	CbGeAlD
Captopril—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.0013	0.0123	CcSEcCtD
Captopril—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.0013	0.0123	CcSEcCtD
Captopril—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00124	0.0118	CcSEcCtD
Captopril—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.0012	0.0114	CcSEcCtD
Captopril—MMP2—spinal cord—amyotrophic lateral sclerosis	0.0012	0.00918	CbGeAlD
Captopril—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.0012	0.0113	CcSEcCtD
Captopril—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00119	0.0113	CcSEcCtD
Captopril—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00119	0.0113	CcSEcCtD
Captopril—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00113	0.0107	CcSEcCtD
Captopril—REN—nervous system—amyotrophic lateral sclerosis	0.0011	0.00841	CbGeAlD
Captopril—LTA4H—brain—amyotrophic lateral sclerosis	0.00109	0.00833	CbGeAlD
Captopril—REN—central nervous system—amyotrophic lateral sclerosis	0.00106	0.0081	CbGeAlD
Captopril—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00106	0.01	CcSEcCtD
Captopril—MMP9—spinal cord—amyotrophic lateral sclerosis	0.00104	0.00798	CbGeAlD
Captopril—REN—cerebellum—amyotrophic lateral sclerosis	0.00103	0.00792	CbGeAlD
Captopril—Tension—Riluzole—amyotrophic lateral sclerosis	0.00102	0.0097	CcSEcCtD
Captopril—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00967	CcSEcCtD
Captopril—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00101	0.0096	CcSEcCtD
Captopril—MMP2—nervous system—amyotrophic lateral sclerosis	0.00101	0.00773	CbGeAlD
Captopril—ACE—embryo—amyotrophic lateral sclerosis	0.000975	0.00747	CbGeAlD
Captopril—MMP2—central nervous system—amyotrophic lateral sclerosis	0.000972	0.00745	CbGeAlD
Captopril—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000966	0.00917	CcSEcCtD
Captopril—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000962	0.00913	CcSEcCtD
Captopril—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000951	0.00903	CcSEcCtD
Captopril—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000939	0.00891	CcSEcCtD
Captopril—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000934	0.00886	CcSEcCtD
Captopril—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00092	0.00873	CcSEcCtD
Captopril—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000915	0.00868	CcSEcCtD
Captopril—F2—spinal cord—amyotrophic lateral sclerosis	0.000909	0.00696	CbGeAlD
Captopril—Cough—Riluzole—amyotrophic lateral sclerosis	0.000909	0.00862	CcSEcCtD
Captopril—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000886	0.00841	CcSEcCtD
Captopril—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000886	0.00841	CcSEcCtD
Captopril—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000886	0.00841	CcSEcCtD
Captopril—MMP9—nervous system—amyotrophic lateral sclerosis	0.000878	0.00673	CbGeAlD
Captopril—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000876	0.00831	CcSEcCtD
Captopril—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000867	0.00823	CcSEcCtD
Captopril—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000857	0.00813	CcSEcCtD
Captopril—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00085	0.00806	CcSEcCtD
Captopril—MMP9—central nervous system—amyotrophic lateral sclerosis	0.000846	0.00648	CbGeAlD
Captopril—REN—brain—amyotrophic lateral sclerosis	0.00084	0.00643	CbGeAlD
Captopril—Shock—Riluzole—amyotrophic lateral sclerosis	0.000836	0.00793	CcSEcCtD
Captopril—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000832	0.00789	CcSEcCtD
Captopril—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000829	0.00787	CcSEcCtD
Captopril—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00081	0.00769	CcSEcCtD
Captopril—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000794	0.00753	CcSEcCtD
Captopril—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000774	0.00735	CcSEcCtD
Captopril—MMP2—brain—amyotrophic lateral sclerosis	0.000772	0.00591	CbGeAlD
Captopril—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000769	0.00729	CcSEcCtD
Captopril—F2—nervous system—amyotrophic lateral sclerosis	0.000766	0.00587	CbGeAlD
Captopril—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000763	0.00724	CcSEcCtD
Captopril—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000763	0.00584	CbGeAlD
Captopril—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000758	0.00719	CcSEcCtD
Captopril—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000755	0.00717	CcSEcCtD
Captopril—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000748	0.0071	CcSEcCtD
Captopril—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000739	0.00701	CcSEcCtD
Captopril—F2—central nervous system—amyotrophic lateral sclerosis	0.000738	0.00565	CbGeAlD
Captopril—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000733	0.00695	CcSEcCtD
Captopril—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000727	0.0069	CcSEcCtD
Captopril—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.0007	0.00664	CcSEcCtD
Captopril—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000695	0.00659	CcSEcCtD
Captopril—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000672	0.00637	CcSEcCtD
Captopril—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000672	0.00637	CcSEcCtD
Captopril—MMP9—brain—amyotrophic lateral sclerosis	0.000671	0.00514	CbGeAlD
Captopril—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00061	0.00579	CcSEcCtD
Captopril—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000601	0.0057	CcSEcCtD
Captopril—SLC22A6—brain—amyotrophic lateral sclerosis	0.0006	0.00459	CbGeAlD
Captopril—F2—brain—amyotrophic lateral sclerosis	0.000586	0.00449	CbGeAlD
Captopril—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000581	0.00552	CcSEcCtD
Captopril—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000562	0.00533	CcSEcCtD
Captopril—ACE—spinal cord—amyotrophic lateral sclerosis	0.000556	0.00425	CbGeAlD
Captopril—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00054	0.00513	CcSEcCtD
Captopril—Rash—Riluzole—amyotrophic lateral sclerosis	0.000536	0.00508	CcSEcCtD
Captopril—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000535	0.00508	CcSEcCtD
Captopril—Headache—Riluzole—amyotrophic lateral sclerosis	0.000532	0.00505	CcSEcCtD
Captopril—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000505	0.00479	CcSEcCtD
Captopril—ACE—nervous system—amyotrophic lateral sclerosis	0.000468	0.00358	CbGeAlD
Captopril—ACE—central nervous system—amyotrophic lateral sclerosis	0.000451	0.00345	CbGeAlD
Captopril—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000437	0.00335	CbGeAlD
Captopril—ALB—brain—amyotrophic lateral sclerosis	0.000374	0.00286	CbGeAlD
Captopril—ACE—brain—amyotrophic lateral sclerosis	0.000358	0.00274	CbGeAlD
Captopril—ABCB1—embryo—amyotrophic lateral sclerosis	0.000343	0.00263	CbGeAlD
Captopril—F2—Peptide ligand-binding receptors—C5AR1—amyotrophic lateral sclerosis	0.000279	0.00286	CbGpPWpGaD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000275	0.00282	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—BDNF—amyotrophic lateral sclerosis	0.000274	0.00281	CbGpPWpGaD
Captopril—MMP2—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—amyotrophic lateral sclerosis	0.000269	0.00276	CbGpPWpGaD
Captopril—MMP9—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.000269	0.00276	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—EXOSC9—amyotrophic lateral sclerosis	0.000268	0.00275	CbGpPWpGaD
Captopril—ALB—Response to elevated platelet cytosolic Ca2+—TUBA4A—amyotrophic lateral sclerosis	0.000267	0.00274	CbGpPWpGaD
Captopril—SLC15A1—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000263	0.0027	CbGpPWpGaD
Captopril—MMP2—Degradation of the extracellular matrix—CASP3—amyotrophic lateral sclerosis	0.000262	0.00268	CbGpPWpGaD
Captopril—ALB—Platelet degranulation—PFN1—amyotrophic lateral sclerosis	0.000252	0.00259	CbGpPWpGaD
Captopril—MMP2—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	0.000251	0.00257	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.00025	0.00256	CbGpPWpGaD
Captopril—LTA4H—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000248	0.00254	CbGpPWpGaD
Captopril—MMP2—Degradation of the extracellular matrix—MMP9—amyotrophic lateral sclerosis	0.000247	0.00253	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—PIGW—amyotrophic lateral sclerosis	0.000242	0.00248	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—ERBB4—amyotrophic lateral sclerosis	0.000241	0.00247	CbGpPWpGaD
Captopril—ALB—Response to elevated platelet cytosolic Ca2+—PFN1—amyotrophic lateral sclerosis	0.00024	0.00246	CbGpPWpGaD
Captopril—MMP2—EPH-Ephrin signaling—MMP9—amyotrophic lateral sclerosis	0.000237	0.00243	CbGpPWpGaD
Captopril—F2—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000233	0.00239	CbGpPWpGaD
Captopril—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000229	0.00175	CbGeAlD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000227	0.00232	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	0.000226	0.00231	CbGpPWpGaD
Captopril—SLC15A1—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000224	0.00229	CbGpPWpGaD
Captopril—MMP9—LPA receptor mediated events—CASP3—amyotrophic lateral sclerosis	0.000223	0.00229	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—XRN2—amyotrophic lateral sclerosis	0.000221	0.00227	CbGpPWpGaD
Captopril—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000221	0.00169	CbGeAlD
Captopril—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000219	0.00168	CbGeAlD
Captopril—MMP9—AGE/RAGE pathway—CASP3—amyotrophic lateral sclerosis	0.000218	0.00223	CbGpPWpGaD
Captopril—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000216	0.00165	CbGeAlD
Captopril—MMP2—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	0.000213	0.00219	CbGpPWpGaD
Captopril—MMP2—EPH-Ephrin signaling—VEGFA—amyotrophic lateral sclerosis	0.000213	0.00218	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000207	0.00213	CbGpPWpGaD
Captopril—SLC15A1—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000199	0.00204	CbGpPWpGaD
Captopril—ALB—Lipoprotein metabolism—APOE—amyotrophic lateral sclerosis	0.000197	0.00202	CbGpPWpGaD
Captopril—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000196	0.0015	CbGeAlD
Captopril—SLC22A6—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000195	0.002	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.000192	0.00197	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	0.000192	0.00197	CbGpPWpGaD
Captopril—MMP9—Endochondral Ossification—VEGFA—amyotrophic lateral sclerosis	0.00019	0.00194	CbGpPWpGaD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000187	0.00192	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—YIF1A—amyotrophic lateral sclerosis	0.000183	0.00188	CbGpPWpGaD
Captopril—CYP2D6—brain—amyotrophic lateral sclerosis	0.000175	0.00134	CbGeAlD
Captopril—ALB—Vitamin B12 Metabolism—SOD1—amyotrophic lateral sclerosis	0.000175	0.00179	CbGpPWpGaD
Captopril—MMP9—Degradation of the extracellular matrix—CASP3—amyotrophic lateral sclerosis	0.000172	0.00176	CbGpPWpGaD
Captopril—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000167	0.00172	CbGpPWpGaD
Captopril—SLC22A6—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000166	0.0017	CbGpPWpGaD
Captopril—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000165	0.00126	CbGeAlD
Captopril—F2—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000161	0.00166	CbGpPWpGaD
Captopril—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000159	0.00121	CbGeAlD
Captopril—MMP2—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	0.000158	0.00161	CbGpPWpGaD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	0.000155	0.00159	CbGpPWpGaD
Captopril—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000155	0.00119	CbGeAlD
Captopril—SLC22A6—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000154	0.00158	CbGpPWpGaD
Captopril—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—amyotrophic lateral sclerosis	0.000154	0.00157	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—EXOSC9—amyotrophic lateral sclerosis	0.000151	0.00155	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.00015	0.00154	CbGpPWpGaD
Captopril—F2—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.00015	0.00154	CbGpPWpGaD
Captopril—SLC22A6—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000148	0.00152	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—PTGS2—amyotrophic lateral sclerosis	0.000148	0.00151	CbGpPWpGaD
Captopril—F2—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000145	0.00149	CbGpPWpGaD
Captopril—F2—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	0.000144	0.00148	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000143	0.00146	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—SOD1—amyotrophic lateral sclerosis	0.000142	0.00146	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	0.000142	0.00145	CbGpPWpGaD
Captopril—MMP9—EPH-Ephrin signaling—VEGFA—amyotrophic lateral sclerosis	0.000139	0.00143	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	0.000137	0.0014	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000136	0.0014	CbGpPWpGaD
Captopril—REN—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	0.000134	0.00137	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000134	0.00137	CbGpPWpGaD
Captopril—LTA4H—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000133	0.00137	CbGpPWpGaD
Captopril—MMP9—AP-1 transcription factor network—TP53—amyotrophic lateral sclerosis	0.000133	0.00137	CbGpPWpGaD
Captopril—ALB—Lipid and lipoprotein metabolism—APOE—amyotrophic lateral sclerosis	0.000131	0.00134	CbGpPWpGaD
Captopril—ALB—Vitamin B12 Metabolism—APOE—amyotrophic lateral sclerosis	0.000129	0.00132	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	0.000127	0.0013	CbGpPWpGaD
Captopril—ABCB1—brain—amyotrophic lateral sclerosis	0.000126	0.000965	CbGeAlD
Captopril—ALB—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	0.000124	0.00127	CbGpPWpGaD
Captopril—LTA4H—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000123	0.00126	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000122	0.00125	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000122	0.00125	CbGpPWpGaD
Captopril—F2—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	0.000122	0.00125	CbGpPWpGaD
Captopril—ALB—Platelet degranulation—SOD1—amyotrophic lateral sclerosis	0.000122	0.00125	CbGpPWpGaD
Captopril—MMP9—Validated targets of C-MYC transcriptional activation—TP53—amyotrophic lateral sclerosis	0.000121	0.00124	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	0.00012	0.00123	CbGpPWpGaD
Captopril—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000119	0.00122	CbGpPWpGaD
Captopril—MMP2—Direct p53 effectors—TP53—amyotrophic lateral sclerosis	0.000117	0.0012	CbGpPWpGaD
Captopril—ALB—Response to elevated platelet cytosolic Ca2+—SOD1—amyotrophic lateral sclerosis	0.000116	0.00119	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000114	0.00116	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000114	0.00116	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.000113	0.00116	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	0.000112	0.00115	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000111	0.00114	CbGpPWpGaD
Captopril—MMP2—Extracellular matrix organization—CASP3—amyotrophic lateral sclerosis	0.00011	0.00112	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	0.000108	0.00111	CbGpPWpGaD
Captopril—F2—Folate Metabolism—TP53—amyotrophic lateral sclerosis	0.000108	0.00111	CbGpPWpGaD
Captopril—MMP2—Extracellular matrix organization—MMP9—amyotrophic lateral sclerosis	0.000104	0.00106	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000102	0.00104	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000101	0.00104	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000101	0.00104	CbGpPWpGaD
Captopril—LTA4H—Metabolism—APOE—amyotrophic lateral sclerosis	0.000101	0.00103	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	9.92e-05	0.00102	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	9.68e-05	0.000992	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	9.44e-05	0.000968	CbGpPWpGaD
Captopril—ALB—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	9.24e-05	0.000947	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	8.88e-05	0.00091	CbGpPWpGaD
Captopril—MMP2—Axon guidance—MMP9—amyotrophic lateral sclerosis	8.79e-05	0.000901	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	8.78e-05	0.0009	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	8.63e-05	0.000884	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	8.56e-05	0.000877	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	8.44e-05	0.000865	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	8.44e-05	0.000865	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	8.42e-05	0.000863	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	8.32e-05	0.000852	CbGpPWpGaD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	8.18e-05	0.000839	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	8.17e-05	0.000837	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	8.07e-05	0.000827	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	8e-05	0.00082	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	7.98e-05	0.000818	CbGpPWpGaD
Captopril—MMP2—Axon guidance—VEGFA—amyotrophic lateral sclerosis	7.9e-05	0.000809	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	7.69e-05	0.000788	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	7.69e-05	0.000788	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	7.52e-05	0.000771	CbGpPWpGaD
Captopril—ALB—Platelet degranulation—IGF1—amyotrophic lateral sclerosis	7.44e-05	0.000762	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	7.4e-05	0.000758	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	7.33e-05	0.000751	CbGpPWpGaD
Captopril—MMP9—Extracellular matrix organization—CASP3—amyotrophic lateral sclerosis	7.19e-05	0.000737	CbGpPWpGaD
Captopril—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—amyotrophic lateral sclerosis	7.09e-05	0.000726	CbGpPWpGaD
Captopril—F2—Hemostasis—SOD1—amyotrophic lateral sclerosis	7.03e-05	0.00072	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	7.01e-05	0.000719	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	6.95e-05	0.000713	CbGpPWpGaD
Captopril—LTA4H—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.91e-05	0.000708	CbGpPWpGaD
Captopril—MMP2—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	6.66e-05	0.000682	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—VCP—amyotrophic lateral sclerosis	6.59e-05	0.000676	CbGpPWpGaD
Captopril—ALB—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	6.41e-05	0.000657	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	6.38e-05	0.000654	CbGpPWpGaD
Captopril—F2—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	6.31e-05	0.000646	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—MMP9—amyotrophic lateral sclerosis	6.28e-05	0.000643	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—C3—amyotrophic lateral sclerosis	6.23e-05	0.000639	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	6.08e-05	0.000624	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	5.99e-05	0.000614	CbGpPWpGaD
Captopril—ALB—Hemostasis—RAB5A—amyotrophic lateral sclerosis	5.96e-05	0.000611	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	5.94e-05	0.000609	CbGpPWpGaD
Captopril—ALB—Hemostasis—PFN1—amyotrophic lateral sclerosis	5.77e-05	0.000591	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	5.72e-05	0.000586	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	5.71e-05	0.000585	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	5.67e-05	0.000581	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	5.64e-05	0.000578	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	5.61e-05	0.000574	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	5.43e-05	0.000557	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	5.41e-05	0.000555	CbGpPWpGaD
Captopril—F2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	5.37e-05	0.00055	CbGpPWpGaD
Captopril—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.33e-05	0.000546	CbGpPWpGaD
Captopril—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.26e-05	0.000539	CbGpPWpGaD
Captopril—MMP9—Axon guidance—VEGFA—amyotrophic lateral sclerosis	5.18e-05	0.000531	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	5.16e-05	0.000528	CbGpPWpGaD
Captopril—F2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	5.09e-05	0.000522	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	5.07e-05	0.000519	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	5.01e-05	0.000513	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	4.97e-05	0.000509	CbGpPWpGaD
Captopril—ALB—Metabolism—TPK1—amyotrophic lateral sclerosis	4.95e-05	0.000507	CbGpPWpGaD
Captopril—ALB—Metabolism—VAPB—amyotrophic lateral sclerosis	4.95e-05	0.000507	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.93e-05	0.000505	CbGpPWpGaD
Captopril—ALB—Platelet degranulation—VEGFA—amyotrophic lateral sclerosis	4.86e-05	0.000498	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	4.85e-05	0.000497	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	4.78e-05	0.00049	CbGpPWpGaD
Captopril—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—amyotrophic lateral sclerosis	4.63e-05	0.000474	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.61e-05	0.000473	CbGpPWpGaD
Captopril—ALB—Metabolism—VAPA—amyotrophic lateral sclerosis	4.52e-05	0.000464	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	4.52e-05	0.000463	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	4.38e-05	0.000449	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	4.38e-05	0.000449	CbGpPWpGaD
Captopril—F2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	4.38e-05	0.000449	CbGpPWpGaD
Captopril—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	4.33e-05	0.000444	CbGpPWpGaD
Captopril—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	4.33e-05	0.000444	CbGpPWpGaD
Captopril—F2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	4.33e-05	0.000444	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	4.3e-05	0.000441	CbGpPWpGaD
Captopril—F2—Hemostasis—IGF1—amyotrophic lateral sclerosis	4.29e-05	0.000439	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	4.28e-05	0.000439	CbGpPWpGaD
Captopril—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.21e-05	0.000431	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	4.08e-05	0.000419	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	4.08e-05	0.000419	CbGpPWpGaD
Captopril—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	3.96e-05	0.000406	CbGpPWpGaD
Captopril—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	3.95e-05	0.000405	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	3.91e-05	0.000401	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.85e-05	0.000395	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	3.84e-05	0.000394	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	3.84e-05	0.000394	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	3.73e-05	0.000383	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	3.7e-05	0.000379	CbGpPWpGaD
Captopril—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.68e-05	0.000378	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.62e-05	0.000371	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.61e-05	0.00037	CbGpPWpGaD
Captopril—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	3.58e-05	0.000366	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.52e-05	0.000361	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.47e-05	0.000356	CbGpPWpGaD
Captopril—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	3.46e-05	0.000355	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.44e-05	0.000353	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	3.42e-05	0.000351	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	3.37e-05	0.000346	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	3.3e-05	0.000338	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	3.26e-05	0.000335	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	3.25e-05	0.000333	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	3.2e-05	0.000328	CbGpPWpGaD
Captopril—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	3.13e-05	0.000321	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.97e-05	0.000305	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	2.95e-05	0.000303	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.94e-05	0.000302	CbGpPWpGaD
Captopril—F2—Hemostasis—VEGFA—amyotrophic lateral sclerosis	2.8e-05	0.000287	CbGpPWpGaD
Captopril—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	2.79e-05	0.000286	CbGpPWpGaD
Captopril—F2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.79e-05	0.000286	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.77e-05	0.000284	CbGpPWpGaD
Captopril—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	2.71e-05	0.000278	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	2.69e-05	0.000276	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.66e-05	0.000272	CbGpPWpGaD
Captopril—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	2.5e-05	0.000256	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	2.5e-05	0.000256	CbGpPWpGaD
Captopril—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	2.5e-05	0.000256	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.45e-05	0.000251	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.37e-05	0.000243	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.28e-05	0.000233	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.28e-05	0.000233	CbGpPWpGaD
Captopril—F2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.27e-05	0.000233	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	2.24e-05	0.000229	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	2.19e-05	0.000225	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	2.16e-05	0.000221	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.14e-05	0.000219	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.12e-05	0.000217	CbGpPWpGaD
Captopril—F2—Hemostasis—TP53—amyotrophic lateral sclerosis	2.12e-05	0.000217	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	2.06e-05	0.000212	CbGpPWpGaD
Captopril—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	2.05e-05	0.00021	CbGpPWpGaD
Captopril—F2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.89e-05	0.000194	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.88e-05	0.000193	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.87e-05	0.000192	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.8e-05	0.000184	CbGpPWpGaD
Captopril—F2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.76e-05	0.00018	CbGpPWpGaD
Captopril—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.7e-05	0.000174	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.7e-05	0.000174	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.6e-05	0.000164	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.45e-05	0.000149	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.45e-05	0.000148	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.28e-05	0.000132	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.23e-05	0.000126	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.12e-05	0.000115	CbGpPWpGaD
Captopril—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.11e-05	0.000114	CbGpPWpGaD
Captopril—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.1e-05	0.000113	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.06e-05	0.000108	CbGpPWpGaD
Captopril—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.01e-05	0.000104	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.67e-06	9.91e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.49e-06	9.73e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.29e-06	9.52e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.11e-06	9.34e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.89e-06	9.11e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	8.39e-06	8.6e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.37e-06	8.58e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	8.35e-06	8.55e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	7.31e-06	7.49e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.17e-06	7.35e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	6.89e-06	7.06e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.72e-06	5.86e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.01e-06	5.13e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.72e-06	4.84e-05	CbGpPWpGaD
